Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.
Xianjun Yu(Fudan University Shanghai Cancer Center), Hui Zhou(Sun Yat-sen University), Jinbo Yue(Shandong Tumor Hospital), Andrea Tazbirkova(Canossa Private Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yingmei Guo, Jian Ruan(Zhejiang Chinese Medical University), Yanru Qin(Zhengzhou University), Meili Sun(Jinan Central Hospital), Zhihua Li(Sun Yat-sen University), Jun Zhang(Tencent (China)), Jia Liu(St Vincent's Hospital Melbourne), Jian Zhang(Shanghai Jiao Tong University), Juan Du(Peking University), Lin Shen(Peking University), Yueyin Pan(University of Science and Technology of China), Yuping Sun(Henan Academy of Agricultural Sciences), Michelle Frances Morris(Sunshine Coast University Hospital), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University)
Cited by 10
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417